highlight
risk
total
infect
upper
respiratori
tract
infect
pharyng
patient
hs
adalimumab
versu
placebo
data
publish
pioneer
ii
trial
patient
hs
take
adalimumab
modest
increas
risk
total
infect
nasopharyng
averag
differ
risk
upper
respiratori
tract
infect
result
demonstr
gener
minim
differ
rate
respiratori
infect
hs
patient
adalimumab
versu
much
like
data
regard
effect
immunosuppress
drug
patient
psoriasi
difficult
extrapol
data
pioneer
ii
trial
suscept
